On the heels of its massive $900 million funding round, Oura, the company behind the personal health tracker the Oura Ring, ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

According to TipRanks.com, Breen is a 3-star analyst with an average return of 7.6% and a 81.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck ...

Squibb announced the oral presentation of the first disclosure of the safety and efficacy data from the global ...

With the S&P 500 ($SPX) surging 26.2% and the Nasdaq ($NDX) soaring 38.2% over the past six months, there’s no denying that ...

Pickering Interfaces will showcase its range of industry-standard modular signal switching and ...

The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies.

The cell and gene therapy drug delivery market plays a pivotal role in advancing precision medicine by ensuring the effective introduction of living cells and genetically modified genes into patients.